These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32865979)

  • 41. The Safety and Benefit of Statins in Liver Cirrhosis: a Review.
    Souk K; Al-Badri M; Azar ST
    Exp Clin Endocrinol Diabetes; 2015 Nov; 123(10):577-80. PubMed ID: 26600051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of statins in cancer prevention and treatment.
    Stamm JA; Ornstein DL
    Oncology (Williston Park); 2005 May; 19(6):739-50; discussion 753-4. PubMed ID: 15971450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statins and myotoxicity: a therapeutic limitation.
    Tiwari A; Bansal V; Chugh A; Mookhtiar K
    Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statins and risk reduction in hepatocellular carcinoma: fact or fiction?
    Singh PP; Singh S
    J Clin Oncol; 2012 Jul; 30(20):2569-70; author reply 2570-2571. PubMed ID: 22689810
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statins: the drugs for the 21st century?
    Ginter E; Simko V
    Bratisl Lek Listy; 2009; 110(10):664-8. PubMed ID: 20017462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statins and plaque stability.
    Gomberg-Maitland M; Fuster V; Fayad ZA; Badimon JJ; Corti R
    J Cardiovasc Risk; 2003 Jun; 10(3):161-7. PubMed ID: 12775948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis.
    Kaplan DE; Serper MA; Mehta R; Fox R; John B; Aytaman A; Baytarian M; Hunt K; Albrecht J; Njei B; Taddei TH;
    Gastroenterology; 2019 May; 156(6):1693-1706.e12. PubMed ID: 30660733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statins and primary liver cancer: a meta-analysis of observational studies.
    Pradelli D; Soranna D; Scotti L; Zambon A; Catapano A; Mancia G; La Vecchia C; Corrao G
    Eur J Cancer Prev; 2013 May; 22(3):229-34. PubMed ID: 23010949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statin inhibition of HMG-CoA reductase: a 3-dimensional view.
    Istvan E
    Atheroscler Suppl; 2003 Mar; 4(1):3-8. PubMed ID: 12714031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of statin therapy on colorectal cancer.
    Bardou M; Barkun A; Martel M
    Gut; 2010 Nov; 59(11):1572-85. PubMed ID: 20660702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
    Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
    Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perioperative statin use: an update.
    Kalarickal PL; Fox CJ; Tsai JY; Liu H; Kaye AD
    Anesthesiol Clin; 2010 Dec; 28(4):739-51. PubMed ID: 21074749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of statins on toll-like receptors: a new insight to pleiotropic effects.
    Bahrami A; Parsamanesh N; Atkin SL; Banach M; Sahebkar A
    Pharmacol Res; 2018 Sep; 135():230-238. PubMed ID: 30120976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.
    Laufs U; Custodis F; Böhm M
    Drugs; 2006; 66(2):145-54. PubMed ID: 16451090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of statins for the primary and secondary prevention of coronary heart disease in women.
    Tziomalos K; Kakafika AI; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Pharm Des; 2009; 15(10):1054-62. PubMed ID: 19355947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The HMG-CoA reductase pathway, statins and angioprevention.
    Feng C; Han A; Ye C; Xu R; Li M
    Semin Ophthalmol; 2006; 21(1):29-35. PubMed ID: 16517442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.